glp-1 and testosterone in women What GLP-1s Mean for Women's Health Menopause and GLP-1 weight-loss drugs

By replenishing B12 levels, Methylcobalamin helps restore energy levels, improve cognitive functions, and promote the overall well-being of the body

In our commitment to covering our communities with innovation and excellence, we incorporate Artificial Intelligence (AI) technologies to enhance our news gathering, reporting, and presentation processes

Prediction model for day 3 embryo implantation potential based on metabolites in spent embryo culture medium

Contact your GP or prescribing clinician if: You experience persistent, severe hunger despite reaching the maintenance dose of 2.4mg weekly for at least 812 weeks You have severe, persistent abdominal pain (with or without vomiting), especially if radiating to the back (possible pancreatitis) seek urgent medical care You develop right upper quadrant pain, fever, or yellowing of the skin/eyes (possible gallbladder disease) seek urgent medical care Hunger is accompanied by other concerning symptoms such as excessive thirst, frequent urination, unexplained weight gain, or fatigue (which may indicate inadequate diabetes control or other metabolic issues) You have gained weight or stopped losing weight despite adherence to dietary and lifestyle recommendations You experience symptoms of hypoglycaemia (low blood sugar), particularly if you have type 2 diabetes or take insulin or sulfonylureas (these medications may need dose adjustment) You experience severe gastrointestinal symptoms (persistent nausea, vomiting, or abdominal pain) that prevent adequate nutritional intake You suspect medication interactions with other prescribed treatments Psychological factors such as depression, anxiety, or disordered eating patterns are significantly impacting your relationship with food Your healthcare provider can assess whether dose adjustment is appropriate, review your overall treatment plan, and investigate potential underlying causes

"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial"

income level (retrieved from the pharmaceutical copayment system that establishes different levels of copayment based on the following income categories: people earning less than 18,000/year, 18,000 to 100,000/year, more than 100,000/year, population exempt from copayment due to socioeconomic vulnerability (labelled in our study as the low resources group), and people without income data (labelled as not available)